Condition: Diabetes Mellitus, Type 1 · Sponsor: Eli Lilly and Company
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| Barbara Davis Center for Childhood Diabetes | Aurora, Colorado, United States | Recruiting |
| Tallahassee Memorial HealthCare | Tallahassee, Florida, United States | Not Yet Recruiting |
| Children's Hospital of Philadelphia (CHOP) | Philadelphia, Pennsylvania, United States | Not Yet Recruiting |
| Driscoll Children's Hospital | Corpus Christi, Texas, United States | Not Yet Recruiting |
| University of Virginia | Charlottesville, Virginia, United States | Recruiting |
| Women's and Children's Hospital | Adelaide, Australia | Recruiting |
| Centre for Children's Health Research | Brisbane, Australia | Not Yet Recruiting |
| Austin Health - Repatriation Hospital | Heidelberg West, Australia | Recruiting |
| Ipswich Hospital | Ipswich, Australia | Recruiting |
| Royal Children's Hospital | Melbourne, Australia | Not Yet Recruiting |
| Southern Adelaide Diabetes & Endocrine Services | Oaklands Park, Australia | Recruiting |
| The Royal Melbourne Hospital | Parkville, Australia | Recruiting |
+ 124 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07222332